ATE444309T1 - Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper - Google Patents
Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörperInfo
- Publication number
- ATE444309T1 ATE444309T1 AT01957479T AT01957479T ATE444309T1 AT E444309 T1 ATE444309 T1 AT E444309T1 AT 01957479 T AT01957479 T AT 01957479T AT 01957479 T AT01957479 T AT 01957479T AT E444309 T1 ATE444309 T1 AT E444309T1
- Authority
- AT
- Austria
- Prior art keywords
- immunotherapy
- myelocytic leukemia
- antibodies
- naked anti
- cronic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22369800P | 2000-08-08 | 2000-08-08 | |
| PCT/US2001/024691 WO2002012347A1 (en) | 2000-08-08 | 2001-08-08 | Immunotherapy for chronic myelocytic leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE444309T1 true ATE444309T1 (de) | 2009-10-15 |
Family
ID=22837639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01957479T ATE444309T1 (de) | 2000-08-08 | 2001-08-08 | Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6759045B2 (de) |
| EP (1) | EP1309627B1 (de) |
| JP (1) | JP3888971B2 (de) |
| CN (1) | CN1468259A (de) |
| AT (1) | ATE444309T1 (de) |
| AU (1) | AU7921701A (de) |
| CA (1) | CA2418014C (de) |
| DE (1) | DE60140063D1 (de) |
| DK (1) | DK1309627T3 (de) |
| WO (1) | WO2002012347A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2275540B1 (de) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Verfahren zur Steuerung der Aktivität von immunologisch funktionellen Molekülen |
| US20040071726A1 (en) * | 2000-09-12 | 2004-04-15 | Chicz Roman M | Peptide epitopes recognized by antigen specific cd4lymphocytes |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| WO2003050257A2 (en) * | 2001-12-06 | 2003-06-19 | University Of Florida | Targeting leukemia cells |
| CA2481304A1 (en) * | 2002-03-27 | 2003-10-09 | Patrick Hwu | Method for treating cancer in humans |
| US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| WO2004043461A1 (en) * | 2002-11-06 | 2004-05-27 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| DK1578446T3 (en) | 2002-11-07 | 2015-06-29 | Immunogen Inc | ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT |
| NZ543635A (en) * | 2003-06-25 | 2008-05-30 | Crucell Holland Bv | Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML |
| US7939058B2 (en) | 2003-07-03 | 2011-05-10 | University Of Southern California | Uses of IL-12 in hematopoiesis |
| DE602004029934D1 (de) | 2003-12-04 | 2010-12-16 | Kyowa Hakko Kirin Co Ltd | Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament |
| CA2561073C (en) * | 2004-03-27 | 2014-01-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Composition and method for cancer treatment |
| US7977320B2 (en) * | 2004-10-29 | 2011-07-12 | The Regents Of The University Of California | Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents |
| US20060234959A1 (en) * | 2005-04-14 | 2006-10-19 | Advanced Photodynamic Technologies, Inc. | Photodynamic therapy utilizing multiple duty cycle light modulation |
| US20060257317A1 (en) * | 2005-05-04 | 2006-11-16 | Duke University | Combination therapy in the treatment of cancer |
| EP1962913B1 (de) * | 2005-11-30 | 2013-12-04 | Therapharm GmbH | Radioimmunokonjugat für humanes cd66 zur behandlung von multiplem myelom |
| US8298544B2 (en) * | 2006-02-27 | 2012-10-30 | Gal Markel | CEACAM based antibacterial agents |
| JP5160412B2 (ja) * | 2006-04-13 | 2013-03-13 | 株式会社医学生物学研究所 | 融合パートナー細胞 |
| US20110038856A1 (en) * | 2006-11-02 | 2011-02-17 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
| WO2011034660A1 (en) * | 2009-09-16 | 2011-03-24 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| DK2839860T3 (da) | 2012-10-12 | 2019-06-17 | Medimmune Ltd | Pyrrolobenzodiazepiner og konjugater deraf |
| ES2687439T3 (es) | 2013-03-13 | 2018-10-25 | Medimmune Limited | Pirrolobenzodiazepinas y conjugados de las mismas |
| MX363787B (es) | 2013-03-13 | 2019-04-03 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de los mismos. |
| KR102066318B1 (ko) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
| EP3193940A1 (de) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepine und konjugate daraus |
| WO2017160954A1 (en) | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| WO2017210621A1 (en) | 2016-06-03 | 2017-12-07 | Seattle Genetics, Inc. | Combination of cd33 antibody drug conjugates with chemotherapeutic agents |
| WO2017214433A1 (en) | 2016-06-09 | 2017-12-14 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with flt3 inhibitors |
| CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| CN117980327A (zh) | 2021-11-03 | 2024-05-03 | 杭州多禧生物科技有限公司 | 抗体的特异性偶联 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4904596A (en) * | 1985-08-07 | 1990-02-27 | Fred Hutchinson Cancer Research Center | Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside |
| IL136051A0 (en) * | 1997-11-10 | 2001-05-20 | Sloan Kettering Inst Cancer | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| US6491917B1 (en) * | 1998-07-31 | 2002-12-10 | Stemcell Technologies Inc. | Antibody composition for debulking blood and bone marrow samples from CML patients |
-
2001
- 2001-08-08 EP EP01957479A patent/EP1309627B1/de not_active Expired - Lifetime
- 2001-08-08 US US09/924,103 patent/US6759045B2/en not_active Expired - Lifetime
- 2001-08-08 DK DK01957479T patent/DK1309627T3/da active
- 2001-08-08 CN CNA018170374A patent/CN1468259A/zh active Pending
- 2001-08-08 WO PCT/US2001/024691 patent/WO2002012347A1/en not_active Ceased
- 2001-08-08 AU AU7921701A patent/AU7921701A/xx active Pending
- 2001-08-08 AT AT01957479T patent/ATE444309T1/de not_active IP Right Cessation
- 2001-08-08 DE DE60140063T patent/DE60140063D1/de not_active Expired - Lifetime
- 2001-08-08 JP JP2002518318A patent/JP3888971B2/ja not_active Expired - Fee Related
- 2001-08-08 CA CA2418014A patent/CA2418014C/en not_active Expired - Fee Related
-
2004
- 2004-05-26 US US10/853,150 patent/US7323168B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002012347A1 (en) | 2002-02-14 |
| CA2418014A1 (en) | 2002-02-14 |
| EP1309627B1 (de) | 2009-09-30 |
| DK1309627T3 (da) | 2009-12-21 |
| US20020022031A1 (en) | 2002-02-21 |
| US20040213796A1 (en) | 2004-10-28 |
| DE60140063D1 (de) | 2009-11-12 |
| CN1468259A (zh) | 2004-01-14 |
| JP2004505994A (ja) | 2004-02-26 |
| JP3888971B2 (ja) | 2007-03-07 |
| CA2418014C (en) | 2014-01-21 |
| US6759045B2 (en) | 2004-07-06 |
| US7323168B2 (en) | 2008-01-29 |
| AU2001279217C1 (en) | 2002-02-18 |
| AU7921701A (en) | 2002-02-18 |
| EP1309627A1 (de) | 2003-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60140063D1 (de) | Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper | |
| MXPA05005726A (es) | Metodos y composiciones para inducir apoptosis en celulas de cancer. | |
| MA42999B1 (fr) | Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë | |
| MX2021007350A (es) | Terapia combinada de cd70 y venetoclax, un inhibidor de bcl-2, para tratar la leucemia mieloide aguda. | |
| CL2007001624A1 (es) | Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular. | |
| CL2012000519A1 (es) | Uso de un anticuerpo aislado o fragmento de enlace antígeno del mismo que comprende una región variable de cadena ligera y una de cadena pesada (sec nº38 y nº40) útil en el tratamiento y prevención de carcinoma de células escamosas en un mamífero (div. sol. 3615-07). | |
| TW200612918A (en) | Lonidamine analogs | |
| IL184617A (en) | Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody | |
| AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
| MA43000B1 (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| AR052774A1 (es) | Inmunoterapia para trastornos autoinmunes | |
| TW200612988A (en) | Adjuvant therapy with the use of anti-glypican 3 antibody | |
| AR023616A1 (es) | Preparaciones combinadas que comprenden derivados de antraciclina | |
| BR0306820A (pt) | Uso de inibidores cox-2 em combinação com agentes antivirais para o tratamento de infecções de papilomavìrus | |
| HRPK20041072B3 (hr) | Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika | |
| BR0213424A (pt) | Uso aperfeiçoado de composto antitumoral na terapia contra câncer | |
| WO2008112129A3 (en) | Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors | |
| AU2001260880A1 (en) | Pharmaceutical compounds for treating copd | |
| MXPA02007899A (es) | Citoquinas modificadas para utilizarse en terapia de cancer. | |
| MY157366A (en) | Therapies and compositions comprising cathepsin s antibodies | |
| IL141550A0 (en) | Methods and compositions for the prevention or treatment of cancer | |
| WO2008066854A3 (en) | Methods and compositions for inducing apoptosis in cancer cells | |
| AU2021334165A8 (en) | Method of treatment of patients having reduced sensitivity to a BCL-2 inhibitor | |
| ATE509630T1 (de) | Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern | |
| GT200000194A (es) | Quimioterapia de combinacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |